The research on the treatment of acute myocardial infarction with Tongxinluo has won recognition from the international medical community

The research on the treatment of acute myocardial infarction with Tongxinluo has won recognition from the international medical community

   On November 16th, the press conference on the results of the National Key R&D Program "Intervention of Cardiovascular Event Chain with the Vein Theory and Health Theory Guidance System" was held in Beijing. Gao Runlin, Zhang Boli, Zhang Yun, Wu Yiling, Han Yaling, academicians of the CAE Member, Shen Jianzhong, deputy director of the China Biotechnology Development Center, and tens of thousands of medical experts and scholars from home and abroad attended the conference online and offline, and more than 7.5 million people watched it online.

   Professor Han Yaling, an academician of the CAE Member and the General Hospital of the Northern Warzone of the Chinese People's Liberation Army, pointed out in her speech at the conference that myocardial infarction is a disease with a very high mortality and disability rate worldwide. Although ST segment elevation myocardial infarction currently uses many reperfusion methods, thrombolysis or interventional treatment, it still faces a very high mortality and disability rate, especially in the case of no reflow injury, the damage to patients is greater, Therefore, we urgently need a new drug or treatment strategy in clinical practice to improve the prognosis of this group of patients.

   Han Yaling pointed out that Tongxinluo capsule is widely used in China as a representative traditional Chinese patent medicines and simple preparations for the treatment of cardiovascular diseases. Through previous series of studies, it has been shown that Tongxinluo capsule can significantly reduce myocardial non reflow, reduce the area of myocardial infarction, effectively protect myocardial cells, and has shown good efficacy and safety in a large number of long-term clinical practices.

Professor Yang Yuejin from Fuwai Hospital of the Chinese Academy of Medical Sciences has led the research on the cardioprotective effect of Zhongguo Tongxin Luo in the treatment of acute myocardial infarction, abbreviated as CTS-AMI study, based on multiple clinical and basic studies for decades. This study further expands the scope of the study

This acute myocardial infarction population confirms its ability to improve clinical outcomes in patients with ST segment elevation myocardial infarction.

"This study is very difficult!" Han Yaling emphasized that she overcame many difficulties during the research process, and after 5 years of effort, she finally achieved fruitful results. The study showed a significant decrease in cardiovascular hard endpoints. It is not easy for traditional Chinese medicine to achieve a decrease in cardiovascular hard endpoints, which was ultimately published in full by JAMA.

Han Yaling also stated that the release of this research result not only demonstrates the strength of Chinese researchers, but also opens up a new path for finding the best combination of traditional Chinese and Western medicine in the treatment of major clinical diseases, bringing thousands of years of traditional Chinese medicine cultural treasures to the world and winning recognition from the international medical community.